Montgomery-Asberg Depression Rating Scale Questionnaire – Talk Bio

Actionable Insights Powered by AI

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

3 weeks ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates

Intra-Cellular’s Caplyta Shows Promising Results in Major Depressive Disorder Study

1 year ago talkbio0Tagged adjunctive therapy, blockbuster label, Caplyta, Clinical Global Impression Original Version Questionnaire, expansion, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, MDD, Montgomery-Åsberg depression rating scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Positive Clinical Trial, Study 501, Unipolar Depression

Intra-Cellular Therapies, Caplyta (lumateperone), Major Depressive Disorder (MDD), Positive clinical trial results, Study 501, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale, Adjunctive therapy, Potential blockbuster label expansion